- Home
- PROK vs DMA Comparison
PROK vs DMA Comparison
Compare PROK & DMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- DMA
- Stock Information
- Founded
- PROK 2015
- DMA 2011
- Country
- PROK United States
- DMA United States
- Employees
- PROK N/A
- DMA N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- DMA Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- DMA Finance
- Exchange
- PROK Nasdaq
- DMA Nasdaq
- Market Cap
- PROK 85.5M
- DMA 77.8M
- IPO Year
- PROK N/A
- DMA N/A
- Fundamental
- Price
- PROK $3.27
- DMA $8.65
- Analyst Decision
- PROK Buy
- DMA
- Analyst Count
- PROK 5
- DMA 0
- Target Price
- PROK $6.25
- DMA N/A
- AVG Volume (30 Days)
- PROK 37.1M
- DMA 34.6K
- Earning Date
- PROK 08-08-2025
- DMA 01-01-0001
- Dividend Yield
- PROK N/A
- DMA 2.04%
- EPS Growth
- PROK N/A
- DMA N/A
- EPS
- PROK N/A
- DMA N/A
- Revenue
- PROK $306,000.00
- DMA N/A
- Revenue This Year
- PROK $85.21
- DMA N/A
- Revenue Next Year
- PROK N/A
- DMA N/A
- P/E Ratio
- PROK N/A
- DMA N/A
- Revenue Growth
- PROK N/A
- DMA N/A
- 52 Week Low
- PROK $0.46
- DMA $4.78
- 52 Week High
- PROK $7.13
- DMA $8.00
- Technical
- Relative Strength Index (RSI)
- PROK 62.08
- DMA 49.81
- Support Level
- PROK $3.17
- DMA $8.63
- Resistance Level
- PROK $4.05
- DMA $8.79
- Average True Range (ATR)
- PROK 1.00
- DMA 0.11
- MACD
- PROK 0.13
- DMA 0.00
- Stochastic Oscillator
- PROK 43.10
- DMA 50.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.